NCT02977052View on ClinicalTrials.gov

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

November 24, 2016

Primary Completion Date

January 3, 2020

Study Completion Date

June 30, 2025

Conditions
Malignant Melanoma Stage III
Interventions
DRUG

Ipilimumab

DRUG

Nivolumab

PROCEDURE

Surgery

Surgery will be done at 6 weeks

PROCEDURE

Blood for PBMCs

Blood will be taken for translational research on PBMCs

PROCEDURE

Biopsies

Biopsies will be taken during screening and at relapse.

Trial Locations (4)

1090

Medical University of Vienna, Vienna

2060

Melanoma Institute Australia, Sydney

1066CX

Netherlands Cancer Institute, Amsterdam

S-171 76

Karolinska Institutet, Stockholm

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER